Detalles de la búsqueda
1.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Lancet
; 402(10404): 798-808, 2023 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37451295
2.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Lancet Oncol
; 24(1): 33-44, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36460017
3.
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Lancet
; 400(10358): 1117-1129, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36099927
4.
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Future Oncol
; 19(16): 1091-1098, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37309702
5.
Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection.
Acta Derm Venereol
; 103: adv10306, 2023 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37902466
6.
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study.
J Eur Acad Dermatol Venereol
; 37(5): 884-893, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36433671
7.
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.
J Eur Acad Dermatol Venereol
; 37(5): 894-906, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36433688
8.
Melanom.
J Dtsch Dermatol Ges
; 21(4): 343-347, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36999586
9.
The effect of mogamulizumab on the aberrant T cell population in the peripheral blood - A monocentric retrospective analysis.
J Dtsch Dermatol Ges
; 21(9): 992-1002, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37401138
10.
S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention.
J Dtsch Dermatol Ges
; 21(11): 1422-1433, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37840404
11.
Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade.
Oncology
; 100(7): 392-398, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35609553
12.
Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS.
Acta Derm Venereol
; 102: adv00695, 2022 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35199180
13.
Histamine Activates Human Eosinophils via H2R and H4R Predominantly in Atopic Dermatitis Patients.
Int J Mol Sci
; 23(18)2022 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36142206
14.
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 848-857, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34000246
15.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 643-654, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33857412
16.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 655-664, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33857414
17.
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 395(10240): 1835-1844, 2020 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32534646
18.
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 395(10236): 1558-1568, 2020 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416781
19.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
N Engl J Med
; 378(19): 1789-1801, 2018 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29658430
20.
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis.
BMC Cancer
; 21(1): 1244, 2021 Nov 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34798846